Expertise in
1
conditions

Omu A. Anzala

Nairobi, KE 
Expertise in
1
conditions
Nairobi, KE 

Overview

Omu Anzala practices practicing medicine in Nairobi, Kenya.

Anzala is highly rated in 1 condition, according to our data. Their clinical expertise encompasses HIV/AIDS, Keloids, Ebola Virus Disease, and Viral Hemorrhagic Fever.

They are actively involved in clinical research, co-authoring 110 peer reviewed articles and participating in 2 clinical trials.

Locations

Nairobi, Kenya
Other Locations
Kenya

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults
A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults
Enrollment Status: Completed
Publish Date: December 14, 2023
Intervention Type: Biological
Study Drug: BG505 SOSIP.664 gp140, Adjuvanted
Study Phase: Phase 1
An Open Label, Phase 2 Study to Evaluate the Safety and Immunogenicity of an Ad26.ZEBOV Booster Dose in Human Immunodeficiency Virus Positive (HIV+) Adults Previously Vaccinated With the Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen
An Open Label, Phase 2 Study to Evaluate the Safety and Immunogenicity of an Ad26.ZEBOV Booster Dose in Human Immunodeficiency Virus Positive (HIV+) Adults Previously Vaccinated With the Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Biological
Study Phase: Phase 2
View 1 Less Clinical Trial

110 Total Publications

VRC01-CLASS PRECURSOR FREQUENCY IN AN AFRICAN POPULATION IS INFLUENCED BY IGHV1-2 ALLELIC COMPOSITION AND NOT MALARIA EXPOSURE.
VRC01-CLASS PRECURSOR FREQUENCY IN AN AFRICAN POPULATION IS INFLUENCED BY IGHV1-2 ALLELIC COMPOSITION AND NOT MALARIA EXPOSURE.
Journal: Research square
Published: July 03, 2026

Frequently Asked Questions about Omu A. Anzala

Is Omu A. Anzala a top-rated expert for HIV/AIDS?

MediFind is an objective health platform that identifies experts based on real-world data. Omu A. Anzala is classified as an Distinguished expert for HIV/AIDS, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Omu A. Anzala participate in research or clinical trials?

Yes. Omu A. Anzala has published 110 articles and abstracts on conditions like HIV/AIDS. You can view a list of Omu A. Anzala's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Anzala's expertise for a condition
ConditionClose
      View All 19 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile